Chugai is starting to implement a new digital platform at manufacturing sites in Japan that it says will improve efficiency and flexibility.
Chugai Pharmaceutical Co., Ltd. has started introducing a novel digitalization process at its domestic plants manufacturing biopharmaceutical products, which is enabling the Japanese firm to optimize workloads by automating planning and the assignment of staff with appropriate skills, while improving remote communication between workers.
The digital platform and "smart plant" idea was implemented at one site in Tokyo last year and is planned for...
The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.
From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.
Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.
